Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration.

J Biomed Sci · 2025 · PMC12172326 · PMID 40524167

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

Additionally, there was an observed trend in drug efficacy in the 3-MP high-dose + CCI treatment group, although it did not reach statistical significance (Fig. 10 F).

also in 249 other papers

did not reach statistical significanceno p-value reported

Additionally, there was an observed trend in drug efficacy in the 3-MP high-dose + CCI treatment group, although it did not reach statistical significance (Fig. 10 F).

also in 53,799 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.